Make use of the data to pick therapies targeting the identified driver(s) and measure survival. Design, SETTING, AND PARTICIPANTS–From 2009 via 2012, 14 web sites in the United states enrolled patients with metastatic lung adenocarcinomas plus a functionality status of 0 by means of two and tested their tumors for ten drivers. Facts was collected on sufferers, therapies, and survival.Kris et al.PageINTERVENTIONS–Tumors have been tested for ten oncogenic drivers, and outcomes had been made use of to select matched targeted therapies.NIH-PA Author Manuscript NIH-PA Author Manuscript NIH-PA Author ManuscriptCopyright 2014 American Medical Association. All rights reserved Corresponding Author: Mark G. Kris, MD, Memorial Sloan Kettering Cancer Center, 300 E 66th St, New York, NY 10065 ([email protected]). Author Contributions: Dr Kris had complete access to all of the information inside the study and takes responsibility for the integrity from the information and also the accuracy of your information analysis. Study idea and design and style: Kris, Johnson, Kwiatkowski, Iafrate, Wistuba, Franklin, Aronson, Camidge, Khuri, Pao, Ladanyi, Kugler, Minna, Bunn. Acquisition, evaluation, or interpretation of information: Kris, Johnson, Berry, Kwiatkowski, Iafrate, Wistuba, Varella-Garcia, Franklin, Su, Shyr, Camidge, Sequist, Glisson, Khuri, Garon, Pao, Rudin, Schiller, Haura, Socinski, Shirai, Giaccone, Chen, Ladanyi, Kugler, Minna, Bunn. Drafting with the manuscript: Kris, Johnson, Varella-Garcia, Shyr, Camidge, Pao, Socinski, Shirai, Giaccone, Chen, Kugler, Minna, Bunn. Essential revision with the manuscript for crucial intellectual content: Kris, Johnson, Berry, Kwiatkowski, Iafrate, Wistuba, VarellaGarcia, Franklin, Aronson, Su, Camidge, Sequist, Glisson, Khuri, Garon, Pao, Rudin, Schiller, Haura, Giaccone, Ladanyi, Minna, Bunn. Statistical analysis: Kris, Johnson, Berry, Su, Shyr, Chen. Obtained funding: Kris, Kwiatkowski, Wistuba, Franklin, Khuri, Pao, Kugler, Bunn. Administrative, technical, or material assistance: Kris, Berry, Kwiatkowski, Iafrate, Wistuba, Varella-Garcia, Franklin, Aronson, Camidge, Khuri, Garon, Pao, Rudin, Haura, Socinski, Giaccone, Ladanyi, Kugler, Bunn. Study supervision: Kris, Kwiatkowski, Iafrate, Varella-Garcia, Franklin, Camidge, Khuri, Rudin, Socinski, Ladanyi, Minna, Bunn. Conflict of Interest Disclosures: All authors have completed and submitted the ICMJE Kind for Disclosure of Potential Conflicts of Interest. Dr Kris reports consulting for Ariad, AstraZeneca, Bind Biosciences, Boehringer Ingelheim, Chugai Pharma, Clovis, Covidien, Daiichi Sankyo, Esanex, Exelixis, and Genentech; receiving grant funding from Boehringer Ingelheim, the National Lung Cancer Partnership (NLCP), Pfizer, PUMA, and Stand as much as Cancer (Massachusetts General Hospital); and receiving payments for lectures from Boehringer Ingelheim, Novartis, Millenium, Pfizer, Roche, China, and Roche, Italy.2619509-30-5 In stock Dr Johnson reports consulting for AstraZeneca and Genentech; holding patents for EGFR mutation testing as indication for EGFR TKI therapy; and getting royalties from Dana-Farber Cancer Institute for EGFR mutation testing.138099-40-8 web Dr Berry reports receiving grant funding from NLCP.PMID:24101108 Dr Kwiatkowski reports consulting for Novartis. Dr Iafrate reports consulting for Bioreference Labs and Pfizer and receiving royalties from Bioreference Labs for licensed SNaPshot technologies. Dr Wistuba reports consulting for Boehringer Ingelheim, GE, Genentech/Roche, GlaxoSmithKline, Novartis, Roche, Pfizer, and Ventana; getting grant funding from AstraZeneca, B.